[Skip to Content]
[Skip to Content Landing]
Views 150
Citations 0
From JAMA's Daily News Site
July 3, 2013

From JAMA’s Daily News Site

JAMA. 2013;310(1):21. doi:10.1001/jama.2013.7753

For women with early-stage breast cancer, examining the tumor’s clinical characteristics and treatment already given is more effective than genetic tests in predicting the likelihood of recurrence more than 5 years after diagnosis, according to a recent study.

The analysis evaluated how effectively 5 scoring methods predicted recurrence in nearly 10 000 postmenopausal women with early-stage breast cancer. All 5 methods performed similarly during the first 5 years of the study. However, during 5 to 10 years of follow-up, the clinical treatment score was most effective in predicting recurrence. Two genetic tests also added significantly to the clinical treatment score’s ability to predict recurrence risk.